Takeda Pharmaceutical (TAK) FCF Payout Ratio Growth (3y) (2021 - 2026)
Powered by 
Analysis
Takeda Pharmaceutical (TAK) FCF Payout Ratio Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | -24.09% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | 32.12% |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | -11.39% |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | - |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn | -4.33% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.33% |
| Sep 30, 2025 | 15.25% |
| Jun 30, 2025 | 18.52% |
| Mar 31, 2025 | 11.90% |
| Dec 31, 2024 | 1.13% |
| Sep 30, 2024 | 8.34% |
| Jun 30, 2024 | 3.33% |
| Mar 31, 2024 | -12.47% |
| Dec 31, 2023 | -9.23% |
| Sep 30, 2023 | 26.45% |
| Jun 30, 2023 | -6.26% |
| Mar 31, 2023 | -21.38% |
| Sep 30, 2022 | 3.24% |
| Jun 30, 2022 | -4.99% |
| Mar 31, 2022 | -2.70% |
| Dec 31, 2021 | 16.62% |
| Sep 30, 2021 | 19.05% |
| Jun 30, 2021 | 14.70% |
| Mar 31, 2021 | 24.08% |